Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Myelofibrosis
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
For information, see Chronic Myeloid Leukemia Treatment.
Sources: Chronic Myeloid Leukemia Treatment
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
To establish a diagnosis of PV, the International Consensus Classification requires that the patient meet either all three major criteria or the first two major criteria with the minor criterion.[1]
Sources: 1
Major Criteria
Hemoglobin greater than 16.5 g/dL in men or 16.0 g/dL in women, hematocrit greater than 49% in men or 48% in women, or elevated red cell mass greater than 25% above mean normal predicted value.
Presence of a JAK2 V617F variant or a JAK2 exon 12 variant.
Bone marrow biopsy showing age-adjusted hypercellularity with trilineage proliferation (panmyelosis), including prominent erythroid, granulocytic, and increase in pleomorphic, mature megakaryocytes without atypia.
Minor Criterion
Serum erythropoietin level below reference range.
There is no staging system for this disease.
Patients have an increased risk of cardiovascular and thrombotic events [2] and leukemic transformation (blast-phase disease) or post-PV myelofibrosis.[3-5] Age older than 67 years, leukocytosis (≥15 × 109/L), a history of thrombosis, and the presence of pathogenic variants (SRSF2) are associated with a poor prognosis.[6]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
The primary therapy for PV includes the use of phlebotomy or cytoreductive therapy to maintain the hematocrit below 45%. This approach was confirmed in a randomized prospective trial, which demonstrated lower rates of cardiovascular death and major thrombosis using this hematocrit target.[7]
Sources: 7
Complications of phlebotomy include:
Thrombocytosis and symptoms related to chronic iron deficiency, including pica, angular stomatitis, and glossitis.
Dysphagia resulting from esophageal webs (very rare).
Potential muscle weakness.
In addition, progressive splenomegaly and pruritus not controllable by antihistamines may persist despite control of the hematocrit by phlebotomy. For more information, see Pruritus.
Sources: Pruritus
If symptoms persist or phlebotomy is not tolerated, cytoreductive therapy can be added to control the disease.
Guidelines based on anecdotal reports have been developed for the management of pregnant patients with PV.[8]
Sources: 8
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Early retrospective studies in patients with PV suggested a superior median survival with myelosuppressive therapy as opposed to either no treatment or treatment with phlebotomy alone. This observation was countered by concerns regarding the leukemogenicity of cytoreductive therapy. The Polycythemia Vera Study Group (PSVG) found that both chlorambucil and radioisotope phosphorous 32 can have leukemogenic potential and are detrimental to survival, but hydroxyurea does not have these effects.[9] Similarly, the leukemic potential of pipobroman and busulfan has been established.[17,18] The leukemogenic hazards of hydroxyurea are still being debated. In several large studies, no consistent association between exposure to hydroxyurea and leukemic transformation (blast-phase MPN) has been identified.
Evidence (frontline cytoreductive therapy):
In an analysis of 51 patients from the PSVG-08 study, the use of hydroxyurea, along with phlebotomy as needed, significantly reduced the risk of thrombosis compared with 134 patients treated with phlebotomy alone from the PSVG-01 study.[19]
Sources: 19
In an analysis of 51 patients from the PSVG-08 study, the use of hydroxyurea, along with phlebotomy as needed, significantly reduced the risk of thrombosis compared with 134 patients treated with phlebotomy alone from the PSVG-01 study.[19]
During the first 7.25 years of observation, there were fewer thrombotic events in patients who received hydroxyurea (9.8%) compared with those who received phlebotomy alone (32.8%) (P = .18). There was no difference in the incidence of leukemic transformation between the two groups at that time point.
With further follow-up (median, 8.6 years; maximum, 15.3 years), leukemic transformation occurred in three patients who received hydroxyurea (5.9%) and two patients who received phlebotomy alone (1.5%) (P = .25). There was no significant difference in the incidence of post-PV myelofibrosis or overall survival between the two groups.[19][Level of evidence C3]
Sources: 19 · Level of evidence C3
The randomized phase III MPN-RC 112 study (NCT01259856) included 87 patients with high-risk PV. Patients were randomly assigned to receive either hydroxyurea or pegylated interferon alfa.[20]
Sources: MPN-RC 112 · 20
The randomized phase III MPN-RC 112 study (NCT01259856) included 87 patients with high-risk PV. Patients were randomly assigned to receive either hydroxyurea or pegylated interferon alfa.[20]
The complete response rates at 12 months were similar between patients who received hydroxyurea or pegylated interferon alfa (30% vs. 28%, respectively).[20][Level of evidence A3]
Sources: 20 · Level of evidence A3
Thrombotic events and disease progression were infrequent in both arms, whereas grade 3 or 4 adverse events were more frequent for patients who received pegylated interferon alfa (46% vs. 28%).
The PROUD-PV study (NCT01949805) randomly assigned 257 patients with an indication for cytoreduction to receive either ropeginterferon alfa-2B or hydroxyurea. Patients could have previously received hydroxyurea for up to 3 years, but with suboptimal response or intolerance. After 1 year, patients could choose to continue study treatment in the CONTINUATION-PV trial (NCT02218047): patients either continued to receive ropeginterferon alfa-2B or received best-available treatment (hydroxyurea or another standard first-line treatment).[13]
Sources: PROUD-PV · CONTINUATION-PV · 13
The PROUD-PV study (NCT01949805) randomly assigned 257 patients with an indication for cytoreduction to receive either ropeginterferon alfa-2B or hydroxyurea. Patients could have previously received hydroxyurea for up to 3 years, but with suboptimal response or intolerance. After 1 year, patients could choose to continue study treatment in the CONTINUATION-PV trial (NCT02218047): patients either continued to receive ropeginterferon alfa-2B or received best-available treatment (hydroxyurea or another standard first-line treatment).[13]
In PROUD-PV, the 12-month complete hematological response rates were similar between the treatment groups (43% for ropeginterferon alfa-2B vs. 46% for hydroxyurea; P = .63).
In PROUD-PV, adverse events resulting in dose reduction occurred in 40% of the patients in the ropeginterferon alfa-2B group and 58% of patients in the hydroxyurea group. Serious treatment-related adverse events occurred in 3 of 127 patients (2%) in the ropeginterferon alfa-2B group and 5 of 127 patients (4%) in the hydroxyurea group.
In CONTINUATION-PV, the 5-year complete hematological response rate (with the last observation carried forward) was 72.6% (69 of 95 patients) in the ropeginterferon alfa-2B group and 52.6% (40 of 76 patients) in the best-available treatment group (rate ratio,1.43; 95% confidence interval [CI], 1.12–1.81; P = .004). The 5-year molecular response rate was 69.1% in the ropeginterferon alfa-2B group and 21.6% in the best-available treatment group (rate ratio, 3.04; 95% CI, 1.96–4.71; P < .0001). Also at 5 years, the median JAK2 V617F allele burden was better for the ropeginterferon alpha-2B group compared with the hydroxyurea group (8% vs. 44%, respectively; P < .0001).[14][Level of evidence A3]
Sources: 14 · Level of evidence A3
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Evidence (posthydroxyurea cytoreductive therapy):
In the phase II MPN-RC 111 study (NCT01259817), 50 patients with PV received pegylated interferon alfa-2a. Patients had previously received hydroxyurea and had either an inadequate response or unacceptable side effects.[12]
Sources: MPN-RC 111 · 12
In the phase II MPN-RC 111 study (NCT01259817), 50 patients with PV received pegylated interferon alfa-2a. Patients had previously received hydroxyurea and had either an inadequate response or unacceptable side effects.[12]
The complete response rate was 22%, and the partial response rate was 38%. A total of 14% of patients discontinued treatment because of side effects.[12][Level of evidence C3]
Sources: 12 · Level of evidence C3
In the open-label RESPONSE study (NCT01243944), patients with phlebotomy-dependent PV and palpable splenomegaly were randomly assigned to receive either ruxolitinib or standard therapy (interferon, pipobroman, anagrelide, immunomodulators, or no treatment/phlebotomy alone). Patients had previously received hydroxyurea but had either an inadequate response or unacceptable side effects.[21]
In the open-label RESPONSE study (NCT01243944), patients with phlebotomy-dependent PV and palpable splenomegaly were randomly assigned to receive either ruxolitinib or standard therapy (interferon, pipobroman, anagrelide, immunomodulators, or no treatment/phlebotomy alone). Patients had previously received hydroxyurea but had either an inadequate response or unacceptable side effects.[21]
Ruxolitinib was superior to standard therapy with regards to phlebotomy-free control of hematocrit (60% vs. 20%; P < .001), reduction of spleen volume (38% vs. 1%; P < .001), and reduction in symptom score by 50% (49% vs. 5%; P < .001).[21][Level of evidence B3]
Sources: 21 · Level of evidence B3
The follow-up open-label RESPONSE-2 study (NCT02038036) included 173 patients with phlebotomy-dependent PV without palpable splenomegaly who had either an inadequate response to or unacceptable side effects from hydroxyurea. Patients were randomly assigned to receive either ruxolitinib or best-available therapy (interferon, pipobroman, anagrelide, immunomodulators, or no treatment/phlebotomy alone).[15]
Sources: RESPONSE-2 · 15
The follow-up open-label RESPONSE-2 study (NCT02038036) included 173 patients with phlebotomy-dependent PV without palpable splenomegaly who had either an inadequate response to or unacceptable side effects from hydroxyurea. Patients were randomly assigned to receive either ruxolitinib or best-available therapy (interferon, pipobroman, anagrelide, immunomodulators, or no treatment/phlebotomy alone).[15]
Hematocrit control was achieved in 62% of patients who received ruxolitinib and 19% of patients who received best-available therapy (hazard ratio [HR], 7.28; 95% CI, 3.43‒15.45; P < .001).[15][Level of evidence B3]
Sources: 15 · Level of evidence B3
MAJIC-PV was a phase II study that randomly assigned 180 patients to receive either ruxolitinib or best-available therapy. Patients had experienced an inadequate response or unacceptable side effects from prior hydroxyurea therapy. Patients remained on study for up to 5 years without crossover.[22]
Sources: 22
MAJIC-PV was a phase II study that randomly assigned 180 patients to receive either ruxolitinib or best-available therapy. Patients had experienced an inadequate response or unacceptable side effects from prior hydroxyurea therapy. Patients remained on study for up to 5 years without crossover.[22]
At 1 year, the complete response rate was 43% for patients who received ruxolitinib and 26% for patients who received best-available therapy (odds ratio, 2.12; 90% CI, 1.25–3.60; P = .02).[22][Level of evidence B1]
Sources: 22 · Level of evidence B1
Thromboembolic event–free survival was significantly higher in the ruxolitinib group compared with the best-available therapy group (HR, 0.58; 95% CI, 0.35–0.94; P = .03).
No randomized trial has compared ruxolitinib with interferons in patients with PV who have previously received hydroxyurea.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
After controlling hematocrit with phlebotomy or cytoreductive therapy, the second principle in treating PV is the use of antiplatelet agents to reduce the risk of thrombosis.
Evidence (antiplatelet therapy):
The double-blind, randomized, phase III European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) studied the use of aspirin in patients with PV.[16]
Sources: 16
The double-blind, randomized, phase III European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) studied the use of aspirin in patients with PV.[16]
Aspirin use was associated with a lower combined risk of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 % CI, 0.18–0.91).[16][Level of evidence B1]
Sources: 16 · Level of evidence B1
The incidence of major bleeding was not significantly increased in the aspirin group.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
To establish a diagnosis of ET, the revised World Health Organization (WHO) classification requires that the patient meet the following criteria:[1]
Sources: 1
Sustained platelet count of at least 450 × 109/L.
Bone marrow biopsy showing predominant proliferation of enlarged mature megakaryocytes; no significant increase of granulocytic or erythroid precursors. This finding distinguishes ET from another entity with thrombocytosis, namely prefibrotic primary myelofibrosis (PMF), which is identified by increased granulocytic or erythroid precursors, atypical megakaryocytes, and increased bone marrow cellularity. Patients with prefibrotic PMF have a worse survival than patients with ET because of an increased progression to myelofibrosis or acute myeloid leukemia.[2-4] Patients with prefibrotic PMF may also have a higher tendency to bleed, which can be exacerbated by low-dose aspirin.[5]
Not meeting criteria for polycythemia vera (PV), PMF, chronic myeloid leukemia, myelodysplastic syndrome, or other myeloid neoplasm.
Demonstration of a JAK2 V617F variant or an MPL exon 10 variant.[6] In the absence of a clonal marker, there must be no evidence for reactive thrombocytosis. In particular, with a decreased serum ferritin, there must be no increase in hemoglobin level to PV range with iron replacement therapy. If a JAK2 variant or an MPL variant is present and other myeloproliferative or myelodysplastic features are excluded, a bone marrow aspirate/biopsy may not be mandatory for diagnosis.[7] About 60% of patients with ET carry a JAK2 variant, and about 5% to 10% of the patients have activating variants in the MPL thrombopoietin receptor gene. About 70% of patients without JAK2 or MPL variants carry a somatic variant in the CALR gene, which is associated with a more indolent clinical course than that seen in patients with JAK2 or MPL variants.[8-12]
Patients older than 60 years or those with a previous thrombotic episode or with leukocytosis have as much as a 25% chance of developing cerebral, cardiac, or peripheral arterial thromboses and, less often, a chance of developing a pulmonary embolism or deep venous thrombosis.[2,13-15] Similar to the other myeloproliferative syndromes, conversion to acute leukemia is found in a small percentage of patients (<10%) with long-term follow-up. Patients younger than 40 years have a more indolent course, with fewer thrombotic events or transformation to acute leukemia.[16] A multivariable analysis in several cohorts that included almost 1,500 patients showed worse outcomes for men, with a hazard ratio (HR) of 1.5 (95% confidence interval [CI], 1.1‒2.5).[17]
There is no staging system for this disease.
Categorizing a patient as having untreated ET means that a patient is newly diagnosed and has had no previous treatment except supportive care.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Initiation of therapy for patients with asymptomatic ET is controversial.[18] In a case-controlled observational study of 65 low-risk patients (age <60 years, platelet count <1,500 × 109/L, and no history of thrombosis or hemorrhage) with a median follow-up of 4.1 years, the thrombotic risk of 1.91 cases per 100 patient-years and hemorrhagic risk of 1.12 cases per 100 patient-years was not increased compared with normal controls.[19]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Treatment options for ET include:
No treatment, unless complications develop, if patients are asymptomatic, younger than 60 years, and have a platelet count of less than 1,500 × 109/L.
Hydroxyurea.[13]
Sources: 13
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Evidence (hydroxyurea):
A prospective randomized trial included 382 patients aged 40 to 59 years with ET and without high-risk factors (no history of thrombosis or bleeding, no hypertension, no diabetes, platelet count ≤1,500 × 109/L). Patients were randomly assigned to receive aspirin alone or hydroxyurea plus aspirin.[28]
Sources: 28
A prospective randomized trial included 382 patients aged 40 to 59 years with ET and without high-risk factors (no history of thrombosis or bleeding, no hypertension, no diabetes, platelet count ≤1,500 × 109/L). Patients were randomly assigned to receive aspirin alone or hydroxyurea plus aspirin.[28]
After a median follow-up of 73 months, there was no difference in thrombosis, hemorrhage, or survival (HR, 0.98; 95% CI, 0.42‒2.25; P = 1.0).[28][Level of evidence B1] Patients younger than 60 years who lacked high-risk factors did not benefit from the addition of hydroxyurea to aspirin.
Sources: 28 · Level of evidence B1
A randomized trial of patients with ET and a high risk of thrombosis compared treatment with hydroxyurea titrated to attain a platelet count below 600 × 109/L with a control group that received no therapy. Hydroxyurea was found to be effective in preventing thrombotic episodes (4% vs. 24%).[13][Level of evidence B3]
Sources: 13 · Level of evidence B3
A randomized trial of patients with ET and a high risk of thrombosis compared treatment with hydroxyurea titrated to attain a platelet count below 600 × 109/L with a control group that received no therapy. Hydroxyurea was found to be effective in preventing thrombotic episodes (4% vs. 24%).[13][Level of evidence B3]
A retrospective analysis of this trial found that antiplatelet drugs had no significant influence on the outcome. Resistance to hydroxyurea was defined as (1) a platelet count of greater than 600 × 109/L after 3 months of at least 2 g per day of hydroxyurea or (2) a platelet count greater than 400 × 109/L and a white blood cell count of less than 2.5 × 109/L or a hemoglobin less than 10 g/dL at any dose of hydroxyurea.[29]
Sources: 29
A prospective randomized trial in the United Kingdom of 809 patients compared hydroxyurea plus aspirin with anagrelide plus aspirin.[30]
Sources: 30
A prospective randomized trial in the United Kingdom of 809 patients compared hydroxyurea plus aspirin with anagrelide plus aspirin.[30]
Although the platelet-lowering effect was equivalent, the anagrelide group had significantly more thrombotic and hemorrhagic events (HR, 1.57; P = .03) and more myelofibrosis (HR, 2.92; P = .01).
No differences were seen for subsequent myelodysplasia or acute leukemia in this trial.[27][Level of evidence B1]
Sources: 27 · Level of evidence B1
Another prospective randomized trial also compared hydroxyurea with anagrelide in 259 previously untreated and high-risk patients.[31] In this central European trial, the diagnosis of ET was made by the WHO recommendations, not by the Polycythemia Vera Study Group criteria as in the U.K. study. This means that patients with leukocytosis and a diagnosis of early prefibrotic myelofibrosis (both groups with much higher rates of thrombosis) were excluded from the central European trial.
Sources: 31
Another prospective randomized trial also compared hydroxyurea with anagrelide in 259 previously untreated and high-risk patients.[31] In this central European trial, the diagnosis of ET was made by the WHO recommendations, not by the Polycythemia Vera Study Group criteria as in the U.K. study. This means that patients with leukocytosis and a diagnosis of early prefibrotic myelofibrosis (both groups with much higher rates of thrombosis) were excluded from the central European trial.
In this analysis, there were no differences in outcome for thrombotic or hemorrhagic events.[31][Level of evidence B1]
Sources: 31 · Level of evidence B1
These randomized prospective trials establish the efficacy and safety for the use of hydroxyurea for patients with high-risk ET (age >60 years + platelet count >1,000 × 109/L or >1,500 × 109/L). For patients diagnosed by WHO standards (excluding patients with leukocytosis and prefibrotic myelofibrosis by bone marrow biopsy), anagrelide represents a reasonable alternative therapy. The addition of aspirin to cytoreductive therapies like hydroxyurea or anagrelide remains controversial, but a retrospective anecdotal report suggested reduction in thrombosis for patients older than 60 years.[32] In a phase II study (NCT01259856), 65 patients with ET who required therapy with hydroxyurea and had either an inadequate response or unacceptable side effects received pegylated interferon alfa-2a. The complete response rate was 43% and the partial response rate was 26%, with only a 14% discontinuation rate from side effects. Patients with a CALR variant had a significantly higher complete response rate than patients without a CALR variant (57% vs. 28%).[33][Level of evidence C3] Unlike results for PV or myelofibrosis, ruxolitinib was not helpful for patients resistant to hydroxyurea.[34]
Sources: 32 · NCT01259856 · 33 · Level of evidence C3 · 34
Many clinicians use hydroxyurea or platelet apheresis prior to elective surgery to reduce the platelet count and to prevent postoperative thromboembolism. No prospective or randomized trials document the value of this approach.
Among low-risk patients (defined as age ≤60 years with no prior thrombotic episodes), a retrospective review of 300 patients showed benefit for antiplatelet agents in reducing venous thrombosis in JAK2-positive cases and in reducing arterial thrombosis in patients with cardiovascular risk factors.[35] Balancing the risks and benefits of aspirin for low-risk patients can be difficult.[36] In an extrapolation of the data from trials of PV, low-dose aspirin to prevent vascular events has been suggested, but there are no data from clinical trials to address this issue.[37,38]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
PMF (also known as agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis, myelosclerosis with myeloid metaplasia, and idiopathic myelofibrosis) is characterized by splenomegaly, immature peripheral blood granulocytes and erythrocytes, and teardrop-shaped red blood cells.[1] In its early phase, the disease is characterized by elevated numbers of CD34-positive cells in the marrow, while the later phases involve marrow fibrosis with decreasing CD34 cells in the marrow and a corresponding increase in splenic and liver engorgement with CD34 cells.
Sources: 1
As distinguished from chronic myeloid leukemia (CML), PMF usually presents as follows:[2]
Sources: 2
A white blood cell count less than 30 × 109/L.
Prominent teardrops on peripheral smear.
Normocellular or hypocellular marrow with moderate to marked fibrosis.
An absence of the Philadelphia chromosome or the BCR::ABL translocation.
In addition to the clonal proliferation of a multipotent hematopoietic progenitor cell, an event common to all chronic myeloproliferative neoplasms, myeloid metaplasia is characterized by colonization of extramedullary sites such as the spleen or liver.[6,7]
Most patients are older than 60 years at diagnosis, and 33% of patients are asymptomatic at presentation. Splenomegaly, sometimes massive, is a characteristic finding. Patients younger than 40 years have a more indolent course, with fewer thrombotic events or transformation to acute leukemia.[8]
Sources: 8
Symptoms of PMF include:
Splenic pain.
Early satiety.
Anemia.
Bone pain.
Fatigue.
Fever.
Night sweats.
Weight loss.
For more information about the symptoms listed above, see Fatigue, Hot Flashes and Night Sweats, and Nutrition in Cancer Care.
Sources: Fatigue · Hot Flashes and Night Sweats · Nutrition in Cancer Care
To establish a diagnosis of PMF, the World Health Organization classification requires that the patient meet all three major criteria and two minor criteria.[9]
Sources: 9
Major Criteria
Megakaryocyte proliferation and atypia, usually accompanied by either reticulin and/or collagen fibrosis; or, in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by increased bone marrow cellularity characterized by granulocytic proliferation and often decreased erythropoiesis (so-called prefibrotic cellular-phase disease).
Not meeting criteria for polycythemia vera (PV), CML, myelodysplastic syndrome, or other myeloid neoplasm.
Demonstration of JAK2 V617F or other clonal marker; or, in the absence of a clonal marker, no evidence of bone marrow fibrosis caused by an underlying inflammatory disease or another neoplastic disease. About 60% of patients with PMF carry a JAK2 variant, and about 5% to 10% of the patients have activating variants in the thrombopoietin receptor gene, MPL. More than half of the patients without JAK2 or MPL carry a somatic pathogenic variant in the CALR gene, which is associated with a more indolent clinical course than that seen in patients with JAK2 or MPL variants.[3-5,10-12]
Minor Criteria
Leukoerythroblastosis.
Increased serum lactate dehydrogenase level.
Anemia.
Palpable splenomegaly.
The major causes of death include:[13]
Sources: 13
Progressive marrow failure.
Transformation to acute nonlymphoblastic leukemia.[14]
Sources: 14
Infection.
Thrombohemorrhagic events.[15]
Sources: 15
Heart failure.
Portal hypertension.
Fatal and nonfatal thrombosis was associated with age older than 60 years and JAK2 V617F positivity in a multivariable analysis of 707 patients followed from 1973 to 2008.[16] Bone marrow examination including cytogenetic testing may exclude other causes of myelophthisis, such as CML, myelodysplastic syndrome, metastatic cancer, lymphomas, and plasma cell disorders.[7] In acute myelofibrosis, patients present with pancytopenia but no splenomegaly or peripheral blood myelophthisis. Peripheral blood or marrow monocytosis is suggestive for myelodysplasia in this setting.
There is no staging system for this disease.
Age 65 years or older.
Anemia (hemoglobin <10 g/dL).
Constitutional symptoms: fever, night sweats, or weight loss.
Leukocytosis (white blood cell count >25 × 109/L).
Circulating blasts of at least 1%.
Patients without any of the adverse features, excluding age, have a median survival of more than 10 to 15 years, but the presence of any two of the adverse features lowers the median survival to less than 4 years.[22,23] International prognostic scoring systems incorporate the aforementioned prognostic factors.[22,24] Thrombocytopenia (platelet count <50 × 109/L) is a very poor prognostic factor for PMF and for myelofibrosis following thrombocythemia or PV.[25]
Karyotype abnormalities can also affect prognosis. In a retrospective series, the 13q and 20q deletions and trisomy 9 correlated with improved survival and no leukemia transformation in comparison with the worse prognosis with trisomy 8, complex karyotype, -7/7q-, i(17q), inv(3), -5/5q-, 12p-, or 11q23 rearrangement.[16,26]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Asymptomatic low-risk patients (based on the aforementioned prognostic systems) should be monitored with a watchful waiting approach. The development of symptomatic anemia, marked leukocytosis, drenching night sweats, weight loss, fever, or symptomatic splenomegaly warrants therapeutic intervention.
The profound anemia that develops in this disease usually requires red blood cell transfusion. Red blood cell survival is markedly decreased in some patients; this can sometimes be treated with glucocorticoids. Disease-associated anemia may occasionally respond to:[7,27-29]
Erythropoietic growth factors. Erythropoietin and darbepoetin are less likely to help when patients are transfusion dependent or manifest a serum erythropoietin level greater than 125 U/L.[30,31]
Prednisone (40–80 mg/day).
Danazol (600 mg/day).
Thalidomide (50 mg/day) with or without prednisone.[32] Patients on thalidomide require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.
Sources: 32
Lenalidomide (10 mg/day) with or without prednisone.[33-35] In the presence of del(5q), lenalidomide with or without prednisone, can reverse anemia and splenomegaly in most patients.[33-35] However, patients receiving lenalidomide require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.
Pomalidomide.[36] Patients on pomalidomide require prophylaxis for avoiding thrombosis and careful monitoring for hematologic toxicity.
Sources: 36
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Ruxolitinib, an inhibitor of JAK1 and JAK2, can reduce the splenomegaly and debilitating symptoms of weight loss, fatigue, and night sweats for patients with JAK2-positive or JAK2-negative PMF, post–essential thrombocythemia myelofibrosis, or post-PV myelofibrosis.[55]
Sources: 55
Evidence (cytoreductive therapy):
In two prospective randomized trials, 528 higher-risk patients were randomly assigned to ruxolitinib or to either placebo (COMFORT-I [NCT00952289]) or best-available therapy (COMFORT-II [NCT00934544]).[37,38]
Sources: COMFORT-I · COMFORT-II · 37 · 38
In two prospective randomized trials, 528 higher-risk patients were randomly assigned to ruxolitinib or to either placebo (COMFORT-I [NCT00952289]) or best-available therapy (COMFORT-II [NCT00934544]).[37,38]
At 48 weeks, patients who received ruxolitinib had a decrease of 30% to 40% in mean spleen volume compared with an increase of 7% to 8% in the control patients.[37,38][Level of evidence B3]
Sources: 37 · 38 · Level of evidence B3
Ruxolitinib also improved overall quality-of-life measures, with low toxic effects in both studies, but with no benefit in overall survival in the initial reports.
Additional follow-up in both studies (5 years in COMFORT-I and in COMFORT-II) showed a survival benefit (statistically significant only for COMFORT-I) among patients who received ruxolitinib compared with control patients (COMFORT-I hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.50–0.96; P = .025; and COMFORT-II HR, 0.67; 95% CI, 0.44–1.02; P = .06).[56,57][Level of evidence A1]
Sources: 56 · 57 · Level of evidence A1
Discontinuation of ruxolitinib results in a rapid worsening of splenomegaly and the recurrence of systemic symptoms.[37-39] Ruxolitinib does not reverse bone marrow fibrosis or induce histological or cytogenetic remissions. Aggressive B-cell lymphomas have occurred among patients treated with ruxolitinib when a preexisting clonal B-cell population was identified at diagnosis in conjunction with myelofibrosis.[60]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Painful splenomegaly can be treated temporarily with ruxolitinib, hydroxyurea, thalidomide, lenalidomide, cladribine, or radiation therapy, but sometimes requires splenectomy.[29,50,61] The decision to perform splenectomy represents a weighing of the benefits (i.e., reduction of symptoms, decreased portal hypertension, and less need for red blood cell transfusions lasting for 1 to 2 years) versus the debits (i.e., postoperative mortality of 10% and morbidity of 30% caused by infection, bleeding, or thrombosis; no benefit for thrombocytopenia; and accelerated progression to the blast-crisis phase that was seen by some investigators but not others).[7,50]
After splenectomy, many physicians use anticoagulation therapy for 4 to 6 weeks to reduce portal vein thrombosis. Hydroxyurea can be used to reduce high platelet levels (>1 million).[62] However, in a retrospective review of 150 patients who underwent surgery, 8% of the patients had a thromboembolism and 7% had a major hemorrhage with prior cytoreduction and postoperative subcutaneous heparin used in one-half of the patients.[63]
Hydroxyurea is useful in patients with splenomegaly but may have a leukemogenic effect.[7] In patients with thrombocytosis and hepatomegaly after splenectomy, cladribine may be an alternative to hydroxyurea.[52] The use of interferon alfa may result in hematological responses, including reduction in spleen size in 30% to 50% of patients, though many patients do not tolerate this medication.[53,54] Favorable responses to thalidomide and lenalidomide have been reported in about 20% to 60% of patients.[27-29,47-49][Level of evidence C3]
Sources: 7 · 52 · 53 · 54 · 27 · 29 · 47 · 49 · Level of evidence C3
A more aggressive approach involves allogeneic peripheral stem cell or bone marrow transplant when a suitable donor is available.[41-46] Allogeneic stem cell transplant is the only potentially curative treatment available, but the associated morbidity and mortality limit its use to younger, high-risk patients.[44,64] Detection of a JAK2 variant after transplant is associated with a worse prognosis.[65]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
CNL is a rare chronic myeloproliferative neoplasm of unknown etiology, characterized by sustained peripheral blood neutrophilia (>25 × 109/L) and hepatosplenomegaly.[1,2] The bone marrow is hypercellular in patients with CNL. No significant dysplasia is in any of the cell lineages, and bone marrow fibrosis is uncommon.[1,2] Cytogenetic studies are normal in nearly 90% of the patients. In the remaining patients, clonal karyotypic abnormalities may include +8, +9, del (20q) and del(11q).[1,3-5] There is no Philadelphia chromosome or BCR::ABL fusion gene. CNL is a slowly progressive disorder, and the survival of patients ranges from 6 months to more than 20 years.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
In the past, the treatment of CNL focused on disease control rather than cure. Once the disease progressed to a more aggressive leukemia, there was typically little chance of obtaining a long-lasting remission because of the older age of most patients, as well as the acquisition of multiple poor prognostic cytogenetic abnormalities. Allogeneic bone marrow transplant represents a potentially curative treatment modality for CNL.[6-8] Results vary with the use of traditional chemotherapies including hydroxyurea and interferon.[9]
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
CEL is a chronic myeloproliferative neoplasm of unknown etiology in which a clonal proliferation of eosinophilic precursors results in persistently increased numbers of eosinophils in the blood, bone marrow, and peripheral tissues. In CEL, the eosinophil count is greater than or equal to 1.5 × 109/L.[1] To make a diagnosis of CEL, there should be evidence for clonality of the eosinophils or an increase in blasts in the blood or bone marrow. However, in many cases, it is impossible to prove clonality of the eosinophils, in which case, if there is no increase in blast cells, the diagnosis of idiopathic hypereosinophilic syndrome (HES) is preferred. Because of the difficulty in distinguishing CEL from HES, the true incidence of these diseases is unknown, although they are rare. In about 10% of patients, eosinophilia is detected incidentally. In others, the constitutional symptoms found include:[1,2]
Fever.
Fatigue.
Cough.
Angioedema.
Muscle pains.
Pruritus.
Diarrhea.
No single or specific cytogenetic or molecular genetic abnormality has been identified in CEL.
For more information about the symptoms listed above, see Hot Flashes and Night Sweats, Fatigue, Cardiopulmonary Syndromes, Pruritus, and Gastrointestinal Complications.
Sources: Hot Flashes and Night Sweats · Fatigue · Cardiopulmonary Syndromes · Pruritus · Gastrointestinal Complications
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024. Captured 2026-09-09.
CEL is rare, and the optimal treatment remains uncertain. The clinical course can range from cases with decades of stable disease to cases with rapid progression to acute leukemia. Case reports suggest that treatment options include bone marrow transplant and interferon alfa.[3,4]
Treatment of HES has included corticosteroids, chemotherapeutic agents (e.g., hydroxyurea, cyclophosphamide, or vincristine), and interferon alfa.[5,6]
Case reports suggest that patients with HES who have not responded to conventional options may have symptomatic responses to imatinib mesylate.[6-8][Level of evidence C3] Imatinib mesylate acts as an inhibitor of a novel FIP1L1::PDGFRA fusion tyrosine kinase, which results as a consequence of an interstitial chromosomal deletion.[6,9][Level of evidence C3] HES with the FIP1L1::PDGFRA fusion tyrosine kinase translocation has been shown to respond to low-dose imatinib mesylate.[9]
Sources: 6 · 8 · Level of evidence C3 · 6 · 9 · Level of evidence C3 · 9
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Prognosis and treatment options depend on:
Sources: Prognosis
the age of the patient
whether the patient has signs or symptoms or other problems related to essential thrombocythemia
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The prognosis depends on:
Sources: prognosis
the age of the patient
the number of abnormal red blood cells and white blood cells
Sources: abnormal
the number of blasts in the blood
whether there are certain changes in the chromosomes
Sources: chromosomes
whether the patient has signs such as fever, drenching night sweats, or weight loss
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
There are different types of treatment for patients with myeloproliferative neoplasms.
The following types of treatment are used:
The following types of treatment are used:
Watchful waiting
Phlebotomy
Platelet apheresis
Transfusion therapy
Chemotherapy
Radiation therapy
Other drug therapy
Surgery
Immunotherapy
Targeted therapy
High-dose chemotherapy with stem cell transplant
New types of treatment are being tested in clinical trials.
Treatment for myeloproliferative neoplasms may cause side effects.
Follow-up care may be needed.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Different types of treatments are available for patients with myeloproliferative neoplasms. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: myeloproliferative neoplasms · standard · clinical trials · research study
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change.
Sources: Watchful waiting · monitoring · signs · symptoms
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Phlebotomy is a procedure in which blood is taken from a vein. A sample of blood may be taken for tests such as a CBC or blood chemistry. Sometimes phlebotomy is used as a treatment and blood is taken from the body to remove extra red blood cells. Phlebotomy is used in this way to treat some myeloproliferative neoplasms.
Sources: Phlebotomy · CBC · blood chemistry · red blood cells
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Platelet apheresis is a treatment that uses a special machine to remove platelets from the blood. Blood is taken from the patient and put through a blood cell separator where the platelets are removed. The rest of the blood is then returned to the patient’s bloodstream.
Sources: platelets
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Blood transfusion is a method of giving red blood cells, white blood cells, or platelets to replace blood cells destroyed by disease or cancer treatment.
Sources: Blood transfusion · white blood cells
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Sources: Chemotherapy · injected · systemic chemotherapy
Learn more at Drugs Approved for Myeloproliferative Neoplasms.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body, such as the spleen, with cancer.
Sources: Radiation therapy · x-rays · radiation · External radiation therapy · spleen
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Prednisone and danazol are drugs that may be used to treat anemia in patients with primary myelofibrosis.
Sources: Prednisone · danazol · anemia · primary myelofibrosis
Anagrelide therapy is used to reduce the risk of blood clots in patients who have too many platelets in their blood. Low-dose aspirin may also be used to reduce the risk of blood clots.
Sources: Anagrelide · blood clots · aspirin
Thalidomide, lenalidomide, and pomalidomide are drugs that prevent blood vessels from growing into areas of tumor cells.
Sources: Thalidomide · lenalidomide · pomalidomide · blood vessels
Erythropoietic growth factors are used to stimulate the bone marrow to make red blood cells.
Sources: Erythropoietic · growth factors · bone marrow
Learn more at Drugs Approved for Myeloproliferative Neoplasms.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Splenectomy (surgery to remove the spleen) may be done if the spleen is enlarged.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.
Sources: Immunotherapy · immune system
Interferon: Interferon affects the division of cancer cells and can slow tumor growth. Interferon alfa and pegylated interferon alpha are commonly used to treat certain myeloproliferative neoplasms.
Sources: Interferon alfa · pegylated interferon alpha
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.
Sources: Targeted therapy
Tyrosine kinase inhibitor (TKI) therapy: TKI therapy blocks signals that cancer cells need to grow. Ruxolitinib is used to treat polycythemia vera and certain types of myelofibrosis.
Sources: Tyrosine kinase inhibitor · Ruxolitinib · polycythemia vera · myelofibrosis
Learn more at Drugs Approved for Myeloproliferative Neoplasms.
Other types of targeted therapies are being studied in clinical trials.
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: Stem cell transplant · Stem cells · donor · infusion
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Learn more at Chronic Myeloid Leukemia Treatment.
Sources: Chronic Myeloid Leukemia Treatment
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The purpose of treatment for polycythemia vera is to reduce the number of extra blood cells. Treatment of polycythemia vera may include:
Sources: polycythemia vera
phlebotomy
Sources: phlebotomy
chemotherapy (hydroxyurea) with or without phlebotomy
Sources: chemotherapy · hydroxyurea
targeted therapy (ruxolitinib), if the chemotherapy does not work
Sources: targeted therapy · ruxolitinib
immunotherapy (pegylated interferon alpha or ropeginterferon alfa-2B)
Sources: immunotherapy · pegylated interferon alpha · ropeginterferon alfa-2B
low-dose aspirin
Sources: aspirin
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of essential thrombocythemia in patients younger than 60 years who have no signs or symptoms and an acceptable platelet count is usually watchful waiting. Treatment of other patients may include:
Sources: essential thrombocythemia · signs · symptoms · platelet · watchful waiting
chemotherapy (hydroxyurea)
Sources: chemotherapy · hydroxyurea
immunotherapy (interferon alfa or pegylated interferon alpha)
Sources: immunotherapy · interferon alfa · pegylated interferon alpha
anagrelide
Sources: anagrelide
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of primary myelofibrosis in patients without signs or symptoms is usually watchful waiting.
Sources: primary myelofibrosis · signs · symptoms · watchful waiting
Patients with primary myelofibrosis may have signs or symptoms of anemia. Anemia is usually treated with transfusion of red blood cells to relieve symptoms and improve quality of life. In addition, anemia may be treated with:
Sources: anemia · transfusion · red blood cells · quality of life
erythropoietic growth factors
Sources: erythropoietic · growth factors
prednisone
Sources: prednisone
danazol
Sources: danazol
thalidomide, lenalidomide, or pomalidomide, with or without prednisone
Sources: thalidomide · lenalidomide · pomalidomide
Treatment of primary myelofibrosis in patients with other signs or symptoms may include:
targeted therapy with ruxolitinib
Sources: targeted therapy · ruxolitinib
chemotherapy (hydroxyurea, cladribine)
Sources: chemotherapy
allogeneic stem cell transplant or bone marrow transplant
Sources: allogeneic stem cell transplant · bone marrow transplant
thalidomide, lenalidomide, or pomalidomide
splenectomy
Sources: splenectomy
radiation therapy to the spleen, lymph nodes, or other areas outside the bone marrow where blood cells are forming
Sources: radiation therapy · spleen · lymph nodes · bone marrow
immunotherapy (interferon alfa)
Sources: immunotherapy · interferon alfa
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of chronic neutrophilic leukemia may include:
Sources: chronic neutrophilic leukemia
allogenic bone marrow transplant
Sources: allogenic bone marrow transplant
chemotherapy
Sources: chemotherapy
immunotherapy (interferon alfa)
Sources: immunotherapy · interferon alfa
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of chronic eosinophilic leukemia may include:
Sources: chronic eosinophilic leukemia
bone marrow transplant
Sources: bone marrow transplant
immunotherapy (interferon alfa)
Sources: immunotherapy · interferon alfa
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Myelofibrosis
ClinicalTrials.gov recordMPN (Myeloproliferative Neoplasms)
ClinicalTrials.gov recordPolycythemia Vera
ClinicalTrials.gov recordHigh Risk Polycythemia Vera, High Risk Essential Thrombocythemia
ClinicalTrials.gov recordHigh Risk Polycythemia Vera, High Risk Essential Thrombocythemia
ClinicalTrials.gov recordPolycythemia Vera
ClinicalTrials.gov recordPolycythemia Vera
ClinicalTrials.gov recordPolycythemia Vera
ClinicalTrials.gov recordAggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia, Relapsed or Refractory Myeloid Malignancies
ClinicalTrials.gov recordAdvanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
ClinicalTrials.gov recordIndolent Systemic Mastocytosis
ClinicalTrials.gov recordPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
ClinicalTrials.gov recordAggressive Systemic Mastocytosis
( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM.
Myeloproliferative Neoplasms
Systemic Mastocytosis with an Associated Myeloid Neoplasm
AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including...
DailyMed labelINDICATIONS AND USAGE GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and...
DailyMed labelPRILOSEC is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of...
DailyMed label